Клинические и гистологические модели и лечение пёдермы гангреносума.

Introduction

Pyoderma gangrenosum (PG), first described by Brocq in 1916 and named by Brunsting et al . in 1930, is a rare non infectious neutrophilic dermatosis that typically presents as destructive cutaneous ulcerations that usually appear on the legs [ 1 , 2 ]. PG can occur at any age; however, it generally presents in the second to fifth decades of life. A century after its first description, we have found out that it was not related to an infection despite its original definition, but we still do not fully understand the pathophysiology of PG. Currently, the loss of innate immune regulation and altered neutrophil chemotaxis are believed to be involved to some extent and considering its association with other auto-inflammatory diseases such as Crohn disease and Behcet´s disease, PG is now included within the spectrum of systemic auto inflammatory diseases [ 1 , 3 ]. The hallmark of the disease is painful ulcerations that can affect any area of the body but are most commonly found in the lower legs.

In the classical type, skin lesions arise suddenly as painful, tender, erythematous papules, plaques, nodules or pustules that rapidly progress to expanding ulcers with characteristic violaceous undermined edges and a necrotic base. Healing of these ulcers usually results in characteristic atrophic cribriform scars [ 1 , 4 , 5 ]. A diagnostic criterion has been also defined [ 6 ]; however, it has not been uniformly accepted according to a study [ 7 ]. Thus, diagnosis is solely based on clinical findings and exclusion of other ulcerating skin diseases [ 1 , 5 ]. PG occurs in association with an underlying disease such as inflammatory bowel disease (IBD), inflammatory arthritis, hematological disorders and solid malignancies in 50% to 70% of the cases [ 4 ].

Thus, investigations are also necessary to determine whether there is a treatable systemic, associated disorder. Remaining cases are rather idiopathic or related to other factors such as trauma or surgery [ 5 , 7 ]. Recent studies of PG associated genetic syndromes may provide insight into the pathogenesis of PG and may help develop specific therapies against new targets [ 3 , 5 ]. PG is a relatively rare disease that makes it difficult to obtain results from randomized controlled studies and treatments are traditionally individualized according to patient compliance and associating systemic diseases. Thus, there is no standard treatment protocol for PG patients [ 1 , 4 , 7 ]. The primary aim of our study was to examine all cases of PG observed in our department over a 6-year period in order to describe the relevant characteristics and outcome under therapy.

Methods

We present a monocentric prospective, observational study included PG patients who were treated between 2009 and 2015 in the Department of Dermatology, University Hospital Hassan II, Fez, Morocco. Cases were identified by screening for patients with a discharge diagnosis of PG that was based on clinical findings and histopathological features consistent with PG together with investigations to exclude other causes including infections, tumors or vasculitis. Age, gender, clinical and histological findings, demographics, comorbidities, therapeutic modalities and outcome were recorded.

Results

Clinical and histopathological characteristics: the clinical characteristics of the patients at diagnosis of PG are summarized in Table 1 . For the 14 patients included (5 women, 9 men; sex ratio H / F = 0.4), the average age at diagnosis was 40.15 years (range: 11-70 years). The classical, ulcerative form was found in 10 cases (71.42%) ( Figure 1 ) and the pustular form in 4 cases (27.57%) ( Figure 2 ). The PG was located preferentially to the lower limbs in 10 cases, trunk, upper limb and neck ( Figure 3 ) in one case each. Histological examination showed a dense infiltrate of neutrophil in all patients, this infiltrate was associated with vasculitis in four cases and lymphoplasmacytic infiltrate in five cases.

Associated diseases: six patients (42,85%) had associated disease at diagnosis of PG, including inflammatory bowel disease in 2 cases (14.28%), a blood disease in 2 cases (14.28%), lymph node tuberculosis and inflammatory arthritis in one case each (7%). In our series one patient was pregnant at 6 month.

Treatments and follow-up: the patients included in the study were followed for varying periods ranging from 3 months to 4 years. Treatment with oral steroids (Prednisone: 0.5-1mg / kg / day) was prescribed first line in 9 cases (64.28%), alone or combined with topical treatment. Topical corticosteroids were used in first line in three cases (21.42%). The remaining two cases were treated with colchicine 1 mg/day.

Discussion

Pyoderma gangrenosum may occur at any age but typically affects those between 20 and 50 years (51.8%), as described by our study and in previous studies [ 8 - 10 ]. In our series we noted a male predominance; however, in most series reported in the literature pyoderma gangrenosum affects women more than men. The clinical characteristics of PG in our study are comparable to published data, with a predominance of the classical ulcerative form. Other clinical variant, bullous, pustular, vegetative and peristomal types are possible but rare. Lesions can appear on any part of the body, but ulcers of the classical subtype favor the lower extremities in up to 85.7% of the patients [ 11 - 13 ], as was the case for 71.42% of our patients. The reason for this specific location is not known [ 13 ]. Binus et al . [ 14 ] found that almost one third of the patients had comorbid conditions such as diabetes and/or peripheral vascular disease and raised the question that these 2 diseases might play a role in and contribute to the development of PG and worsen local healing processes, especially on the lower leg.

The diagnosis of PG relies on clinical signs first and is supported by biopsy for histopathology. Knowledge of the patient's history for possible underlying disease and specific investigations based on that background are necessary. Therefore, diagnosis is made by exclusion of other possible disorders. No laboratory parameter for PG is available. The histopathology of PG is no specific and changes with the stage of lesion. The initial lesions show a deep suppurative folliculitis with dense neutrophilic infiltrate. In about 40% of cases, leukocytoclastic vasculitis is present as was in four of our cases. PG with (necrotizing) granulomatous inflammation has been described [ 15 - 17 ]. An associated disease, similar to those observed in other neutrophilic dermatosis, was found in 42.85% of our patients, which is consistent with the literature, where the frequency of pathological associations is between 33 and 84% [ 1 , 18 - 20 ].

IBD was identified in 14.28% of cases (20% to 30% in the literature), a blood disease in 14,28% of cases (15% to 25% in the literature), inflammatory arthritis in 7% of cases (20% to 30% in the literature) and ganglionic tuberculosis in 7% of our cases (extremely rare association in the literature). However, thyroid diseases (including cancer of the thyroid) were very rare [ 18 ]. Because the etiology of the disease is not being understood, there is no specific and uniformly effective therapy for PG. The aim of the treatment is to reduce pain and to promote wound healing by reducing inflammation with anti-inflammatory and immunosuppressive agents, thereby improving the quality of life of PG patients.

Thus for extended and active lesions, treatments which have shown efficacy in several case series are oral corticosteroid therapy with prednisone doses ranging from 40 to 120 mg per day in adults and cyclosporine (average dose of 5 to 7 mg / kg / day) [ 21 - 23 ]. Our study had some limitations related to the assessment of a small number of PG patients and patient recruitment through the only dermatology department which was originally a selection bias. Thus, the results of this study need to be confirmed by multicenter studies with large number of patients and especially by involving other specialists for patient recruitment.

Conclusion

Our study confirms that the PG is a rare disease, associated in almost half of cases with systemic disease already present at diagnosis; it is most often IBD, blood disorders, solid cancers and tuberculosis in our Moroccan background.

What is known about this topic

PG a rare inflammatory neutrophilic dermatosis; Association with systemic diseases.

What this study adds

The first study of PG in Morocco; Tuberculosis association with PG in our background.

Competing interests

The authors declare no competing interests.

Authors’ contributions

All the authors have read and agreed to the final manuscript.

1. Ahronowitz I Harp J Shinkai K Etiology and management of pyoderma gangrenosum: a comprehensive review Am J Clin Dermatol 2012 13 3 191 211 22356259 10.2165/11595240-000000000-00000

2. Gameiro A Pereira N Cardoso JC Goncalo M Pyoderma gangrenosum: challenges and solutions Clin Cosmet Investig Dermatol 2015 8 285 293 10.2147/CCID.S61202 PMC4454198 26060412

3. Braswell SF Kostopoulos TC Ortega-Loayza AG Pathophysiology of pyoderma gangrenosum (PG): an updated review J Am Acad Dermatol 2015 73 4 691 698 26253362 10.1016/j.jaad.2015.06.021

4. Ruocco E Sangiuliano S Gravina AG Miranda A Nicoletti G Pyoderma gangrenosum: an updated review J Eur Acad Dermatol Venereol 2009 23 9 1008 1017 19470075 10.1111/j.1468-3083.2009.03199.x

5. Patel F Fitzmaurice S Duong C He Y Fergus J Raychaudhuri SP et al Effective strategies for the management of pyoderma gangrenosum: a comprehensive review Acta Derm Venereol 2015 95 5 525 531 25387526 10.2340/00015555-2008

6. Su WP Davis MD Weenig RH Powell FC Perry HO Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria Int J Dermatol 2004 43 11 790 800 15533059 10.1111/j.1365-4632.2004.02128.x

7. Wollina U Pyoderma gangrenosum: a systemic disease Clin Dermatol 2015 33 5 527 530 26321398 10.1016/j.clindermatol.2015.05.003

8. Powell FC Schroeter AL Su WP Perry HO Pyoderma gangrenosum: a review of 86 patients Q J Med 1985 55 217 173 186 3889978

9. Ye MJ Ye JM Pyoderma gangrenosum: a review of clinical features and outcomes of 23 cases requiring inpatient management Dermatol Res Pract 2014 10 8 2014 461467 25374597 10.1155/2014/461467 PMC4206920

10. Adisen E Erduran F Gürer MA Pyoderma gangrenosum: a report of 27 patients Int J Low Extrem Wounds 2016 Juin 15 2 148 54 27009790 10.1177/1534734616639172

11. Von den Driesch P Pyoderma gangrenosum: a report of 44 cases with follow-up Br J Dermatol 1997 137 6 1000 1005 9470924

12. Mlika RB Riahi I Fenniche S Mokni M Dhaoui MR Dess N et al Pyoderma gangrenosum: a report of 21 cases Int J Dermatol 2002 41 2 65 68 11982638 10.1046/j.1365-4362.2002.01329.x

13. Pereira N Brites MM Goncalo M Tellechea O Figueiredo A Pyoderma gangrenosum a review of 24 cases observed over 10 years Int J Dermatol 2013 52 8 938 945 23676016 10.1111/j.1365-4632.2011.05451.x

14. Binus AM Qureshi AA Li VW Winterfield LS Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients Br J Dermatol 2011 165 6 1244 1250 21824126 10.1111/j.1365-2133.2011.10565.x

15. Crowson AN Mihm MC Jr Magro C Pyoderma gangrenosum: a review J Cutan Pathol 2003 30 2 97 107 12641787 10.1034/j.1600-0560.2003.00024.x

16. Su WP Schroeter AL Perry HO Powell FC Histopathologic and immunopathologic study of pyoderma gangrenosum J Cutan Pathol 1986 13 5 323 330 3537032 10.1111/j.1600-0560.1986.tb00466.x

17. Park HJ Kim YC Cinn YW Yoon TY Granulomatous pyoderma gangrenosum: two unsual cases showing necrotizing granulomatous inflammation Clin Exp Dermatol 2000 25 8 617 620 11167975 10.1046/j.1365-2230.2000.00721.x

18. Al Ghazal P Herberger K Shaller G Strölin A Hoff NP Goerge T et al Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients Orphanet J Rare Dis 2013 8 136 24010984 10.1186/1750-1172-8-136 PMC3844435

19. Langan SM Groves RW Card TR Gulliford MC Incidence, mortality and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study J Invest Dermatol 2012 132 9 2166 70 22534879 10.1038/jid.2012.130

20. Duarte AF Nogueira A Lisboa C Azevedo F Pyoderma gangrenosum-clinical, laboratory and therapeutic approaches: review of 28 cases Dermatol Online J 2009 15 7 3 19903431

21. Powell F Su W Perry H Pyoderma gangrenosum: classification and management J Am Acad Dermatol 1996 34 3 395 409 8609250 10.1016/s0190-9622(96)90428-4

22. Teagle A Hargest R Management of pyoderma gangrenosum JR Soc Med 2014 107 6 228 36 10.1177/0141076814534407 PMC4109146 24912791

23. Dabade TS Davis MD Diagnosis and treatment of the neutrophilic dermatoses (pyoderma gangrenosum, Sweet´s syndrome) Dermatol Ther 2011 24 2 273 84 21410617 10.1111/j.1529-8019.2011.01403.x